BALCHEM CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 139.3 USD | +0.55% |
|
-2.94% | -6.38% |
| 03-29 | Balchem Corporation Announces Management Changes | CI |
| 03-12 | Balchem Insider Sold Shares Worth $840,985, According to a Recent SEC Filing | MT |
| Sales 2024 * | 965M 77.26B | Sales 2025 * | 1.02B 81.48B | Capitalization | 4.49B 360B |
|---|---|---|---|---|---|
| Net income 2024 * | 128M 10.25B | Net income 2025 * | 145M 11.61B | EV / Sales 2024 * | 4.77 x |
| Net Debt 2024 * | 111M 8.87B | Net cash position 2025 * | 40.28M 3.22B | EV / Sales 2025 * | 4.38 x |
| P/E ratio 2024 * |
35.4
x | P/E ratio 2025 * |
31.2
x | Employees | 1,302 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.03% |
More Fundamentals
* Assessed data
More news
Latest transcript on Balchem Corporation
More recommendations
More press releases
| 1 day | +0.55% | ||
| 1 week | -2.94% | ||
| Current month | -10.13% | ||
| 1 month | -9.84% | ||
| 3 months | -0.12% | ||
| 6 months | +21.01% | ||
| Current year | -6.38% |
1 week
137.79
145.52
1 month
137.79155.45
Current year
135.84159.52
1 year
110.74159.52
3 years
110.15174.29
5 years
78.30174.29
10 years
48.89174.29
| Managers | Title | Age | Since |
|---|---|---|---|
Theodore Harris
CEO | Chief Executive Officer | 59 | 27/04/15 |
Martin Bengtsson
DFI | Director of Finance/CFO | 47 | 03/02/19 |
Michael Sestrick
CTO | Chief Tech/Sci/R&D Officer | 61 | 31/12/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Daniel Knutson
BRD | Director/Board Member | 67 | 31/01/18 |
Theodore Harris
CEO | Chief Executive Officer | 59 | 27/04/15 |
| Director/Board Member | 57 | 14/09/15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.90% | 1 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 139.3 | +0.55% | 58,508 |
| 25/04/24 | 138.5 | -1.52% | 111,231 |
| 24/04/24 | 140.6 | -3.05% | 119,526 |
| 23/04/24 | 145.1 | +0.94% | 70,624 |
| 22/04/24 | 143.7 | +0.17% | 64,336 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. The Company's segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. Through Specialty Products, it re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.
Sector
Specialty Chemicals
Calendar
03/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
139.3
USD
Average target price
154.8
USD
Spread / Average Target
+11.12%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.38% | 4.49B | |
| +11.47% | 63.22B | |
| -3.47% | 46.34B | |
| +13.72% | 39.97B | |
| +17.83% | 25.46B | |
| +7.27% | 18.68B | |
| -0.57% | 17.24B | |
| -21.73% | 15.81B | |
| +0.22% | 14.9B | |
| -19.10% | 13.74B |
- Stock Market
- Equities
- BCPC Stock
